Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy and safety of TV-1380
[Recombinant human serum albumin (HSA) mutated butyrylcholinesterase (AlbuBChE)] in
facilitating abstinence in cocaine-dependent subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries